CCL21 and neoplasm: Various in vitro and in vivo experiments have validated the potential of SLC inhibitors, such as JPH203, AZD3965, BAY‐8002 and 7ACC2, to alter tumour cell metabolism and impede tumour growth.9, 41, 42